er in t47d er+ cells

ERD-308 induces >95% of ER degradation at concentrations as low as 5 nM in both cell lines (DC50 (concentration causing 50% of protein degradation) of 0.17 nM and 0.43 nM in MCF-7 and T47D ER+ cells, respectively).ERD-308 is a highly potent PROTAC degrade

(E Z)-Droloxifene 是 (E)-Droloxifene 和 (Z)-Droloxifene 的混合物，其中 (E)-Droloxifene 是一种选择性雌激素受体调节剂。在兔子子宫匀浆实验中，(E)-Droloxifene 结合雌激素受体 (ER) 的 IC50 值为 24 nM。它能够增加未成熟大鼠的子宫重量，并减少雌二醇诱导的幼年大鼠子宫重量增加。此外，(E)-Droloxifene 抑制 17β-雌二醇刺激的 MCF-7、ZR-75-1 和 T47D 人乳腺癌细胞的生长。(Z)-Droloxifene 则由于与 ER 结合较弱，无雌激素或抗雌激素活性。

17β-hydroxy Exemestane is the primary active metabolite of exemestane . It is formed by metabolism of exemestane by the cytochrome P450 (CYP) isoforms CYP1A and CYP4A11. 17β-hydroxy Exemestane is an aromatase inhibitor (IC50 = 69 nM using human placental microsomes) and an androgen receptor (AR) agonist (IC50 = 39.6 nM) that is selective for AR over estrogen receptor α (ERα; IC50 = 21.2 μM). It stimulates growth of AR- and ERα-positive MCF-7 (EC50 = 2.7 μM) and T47D breast cancer cells (EC50s = 0.43 and 1,500 nM for AR- and ER-mediated growth, respectively) and inhibits proliferation of testosterone-treated aromatase-overexpressing MCF-7aro cells in a concentration-dependent manner. 17β-hydroxy Exemestane (20 mg/kg) inhibits increases in serum cholesterol and LDL levels and prevents decreases in bone mineral density in the lumbar vertebrae and femur, as well as femoral bending strength and compressive strength of the fifth lumbar vertebrae, in ovariectomized rats.

ER degrader 7 (Compound 35t) 是一种既能降解ERα又能降解ERβ的化合物。该化合物具有抑制微管蛋白聚合的功能，并能有效降低多种细胞系（包括MCF-7、T47D、MCF-10A、LCC2、T47D D538G与T47D Y537S）的细胞活性，相应IC50s值分别为0.06、2.56、15.84、1.59、1.67、1.37 μM。此外，ER degrader 7 对乳腺癌肿瘤生长同样有抑制作用。

ERα17p (ERα 295-311)作为雌激素受体α (ER) 的钙调蛋白 (CaM) 结合表位，在钙依赖的方式下与CaM发生作用。该化合物通过Rho ROCK和PI3K Akt信号通路，调控包括MCF-7、SK-BR-3、T47D及MDA-MB-231在内的多种癌细胞迁移。同时，ERα17p对乳腺癌细胞的抑制作用包括减缓细胞增殖、诱发细胞凋亡 (apoptosis)，以及在小鼠模型中抑制肿瘤生长。